ABSTRACT
Inflammatory illness is associated with depression. Preclinical work has shown that chemokines are linked with peripheral-central crosstalk and may be important in mediating depressive behaviours. We sought to establish what evidence exists that differences in blood or cerebrospinal fluid chemokine concentration discriminate between individuals with depression and those without. Following PRISMA guidelines, we systematically searched Embase, PsycINFO and Medline databases. We included participants with physical illness for subgroup analysis, and excluded participants with comorbid psychiatric diagnoses. Seventy-three studies met the inclusion criteria for the meta-analysis. Individuals with depression had higher levels of blood CXCL4 and CXCL7 and lower levels of blood CCL4. Sensitivity analysis of studies with only physically healthy participants identified higher blood levels of CCL2, CCL3, CCL11, CXCL7 and CXCL8 and lower blood levels of CCL4. All other chemokines examined did not reveal significant differences (blood CCL5, CCL7, CXCL9, CXCL10 and cerebrospinal fluid CXCL8 and CXCL10). Analysis of the clinical utility of the effect size of plasma CXCL8 in healthy individuals found a negative predictive value 93.5%, given the population prevalence of depression of 10%. Overall, our meta-analysis finds evidence linking abnormalities of blood chemokines with depression in humans. Furthermore, we have demonstrated the possibility of classifying individuals with depression based on their inflammatory biomarker profile. Future research should explore putative mechanisms underlying this association, attempt to replicate existing findings in larger populations and aim to develop new diagnostic and therapeutic strategies.
Subject(s)
Chemokines/metabolism , Depression/etiology , Depression/metabolism , Inflammation/complications , Inflammation/metabolism , Databases, Factual/statistics & numerical data , HumansABSTRACT
Intestinal damage and severe diarrhea are serious side effects of cancer chemotherapy and constrain the usage of most such therapies. Here we show that interleukin-33 (IL-33) mediates the severe intestinal mucositis in mice treated with irinotecan (CPT-11), a commonly used cancer chemotherapeutic agent. Systemic CPT-11 administration led to severe mucosal damage, diarrhea, and body weight loss concomitant with the induction of IL-33 in the small intestine (SI). This mucositis was markedly reduced in mice deficient in the IL-33R (ST2(-/-)). Moreover, recombinant IL-33 exacerbated the CPT-11-induced mucositis, whereas IL-33 blockade with anti-IL-33 antibody or soluble ST2 markedly attenuated the disease. CPT-11 treatment increased neutrophil accumulation in the SI and adhesion to mesenteric veins. Supernatants from SI explants treated with CPT-11 enhanced transmigration of neutrophils in vitro in an IL-33-, CXCL1/2-, and CXCR2-dependent manner. Importantly, IL-33 blockade reduced mucositis and enabled prolonged CPT-11 treatment of ectopic CT26 colon carcinoma, leading to a beneficial outcome of the chemotherapy. These results suggest that inhibition of the IL-33/ST2 pathway may represent a novel approach to limit mucositis and thus improve the effectiveness of chemotherapy.
Subject(s)
Camptothecin/analogs & derivatives , Colonic Neoplasms/therapy , Interleukin-33/antagonists & inhibitors , Mucositis/chemically induced , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Blotting, Western , Camptothecin/pharmacology , Cell Line, Tumor , Drug Synergism , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33/genetics , Interleukin-33/pharmacology , Irinotecan , Mice , Mice, Inbred BALB C , Mucositis/prevention & control , Receptors, Interleukin/metabolism , Recombinant Proteins/pharmacologyABSTRACT
Regulatory T cells (T(regs) ) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self- and tumour-associated antigens, T(regs) are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti-tumour responses. Suppression mechanisms employed by T(regs) are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti-tumour responses. This review will focus on the current evidence supporting the central role of T(regs) in establishing tumour-specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of T(regs) accumulation within the tumour, including enhanced recruitment, in-situ or local proliferation, and de-novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of T(regs) . The role of T(regs) is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies.
Subject(s)
Immune Tolerance/immunology , Neoplasms/immunology , T-Lymphocytes, Regulatory/immunology , Tumor Escape/immunology , Animals , Antineoplastic Agents/therapeutic use , Disease Progression , Humans , Immune Tolerance/drug effects , Mice , Neoplasms/drug therapy , Prognosis , T-Lymphocytes, Regulatory/drug effects , Tumor Escape/drug effects , Tumor Microenvironment/immunologyABSTRACT
A subset of chemokine receptors, initially called "silent" on the basis of their apparent failure to activate conventional signalling events, has recently attracted growing interest due to their ability to internalize, degrade, or transport ligands and thus modify gradients and create functional chemokine patterns in tissues. These receptors recognize distinct and complementary sets of ligands with high affinity, are strategically expressed in different cellular contexts, and lack structural determinants supporting Gα(i) activation, a key signalling event in cell migration. This is in keeping with the hypothesis that they have evolved to fulfil fundamentally different functions to the classical signalling chemokine receptors. Based on these considerations, these receptors (D6, Duffy antigen receptor for chemokines (DARC), CCX-CKR1 and CXCR7) are now collectively considered as an emerging class of 'atypical' chemokine receptors. In this article, we review the biochemistry and biology of this emerging chemokine receptor subfamily.
Subject(s)
Duffy Blood-Group System/immunology , Receptors, CCR/immunology , Receptors, CXCR/immunology , Receptors, Cell Surface/immunology , Receptors, Chemokine/immunology , Animals , Biological Evolution , Humans , Immunomodulation , Signal Transduction , TranscytosisABSTRACT
Selective sequestration of inflammatory chemokines is critical for the successful resolution of inflammatory responses in vivo. D6 is an atypical chemokine receptor that scavenges inflammatory chemokines and is pivotal in resolving models of chemokine-driven cutaneous inflammation. We provide evidence that expression of D6 is not limited to the lymphatic endothelium at sites of inflammation as previously believed. Instead we postulate that D6 expression in leucocytes may have a significant impact upon chemokine bioavailability during the resolution phase of inflammation. D6 expressed on the lymphatic endothelia may instead have complementary roles in preventing inappropriate leucocyte migration to the lymph node by keeping the endothelium free from inflammatory chemokines.
Subject(s)
Inflammation/physiopathology , Receptors, Chemokine/physiology , Animals , Humans , Macrophages/physiology , Mice , Receptors, CCR10 , Chemokine Receptor D6ABSTRACT
Macrophage inflammatory protein-1alpha (MIP-1alpha) is a member of the chemokine family of proinflammatory mediators. In addition to its inflammatory roles, MIP-1alpha has been shown to be active as an inhibitor of primitive hemopoietic cell proliferation. Indeed, a dysfunction in this inhibitory process has been postulated to contribute to leukemogenesis. Research has been aimed at characterizing the receptor involved in cellular inhibition by MIP-1alpha. This study demonstrates that of all the beta-chemokines tested, only MIP-1alpha is capable of inhibiting primitive hemopoietic cell proliferation. Because no MIP-1alpha-specific receptors have been identified, this suggests that inhibition is mediated by an uncharacterized receptor. Further evidence for the involvement of a novel receptor in this process is the equivalent potencies of MIP-1alphaS and MIP-1alphaP variants of human MIP-1alpha and the fact that primitive cells from bone marrow derived from individual MIP-1alpha receptor null mice display a full response to MIP-1alpha inhibition.
Subject(s)
Cell Division/drug effects , Hematopoietic Stem Cells/cytology , Macrophage Inflammatory Proteins/pharmacology , Receptors, Chemokine/physiology , Animals , Bone Marrow Cells/cytology , Chemokine CCL3 , Chemokine CCL4 , Mice , Mice, Knockout , Receptors, Chemokine/deficiencyABSTRACT
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5(+) B cells. This B-cell lineage is established during ontogeny and replenished by the process of self-renewal. Spontaneous and induced leukaemias that frequently affect this lineage are thought to arise as a result of the frequent cell division required to maintain the population throughout adulthood and in response to repeated exposure to environmental antigens. In a series of bone marrow transplant (BMT) experiments performed in B6D2F1 mice, B-cell leukaemia occurred in recipients of serially transplanted syngeneic bone marrow. This study was therefore designed to determine the frequency and phenotype of the observed leukaemia. Male donor cells were initially transplanted into lethally irradiated female hosts and secondary (2 degrees ) BMT was performed at 3 months. At 1, 2, 3 and 16 months following primary (1 degrees ) BMT, and when 2 degrees BMT recipients developed leukaemia, animals were sacrificed and their tissues extensively examined. These analyses confirmed a host-derived CD5(+) transplantable B-cell leukaemia that was initiated in 50% of 1 degrees BMT recipients. With serial passage, the leukaemia became more aggressive and lost CD5 expression, suggesting transformation to a high-grade leukaemia/lymphoma. This previously unreported observation suggests that the combination of radiation and subsequent serial transplantation induces a proliferative stress to the host B-cell compartment that is causative in leukaemic transformation.
Subject(s)
B-Lymphocytes/immunology , Bone Marrow Transplantation/adverse effects , CD5 Antigens , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Animals , Blotting, Southern , Female , In Situ Hybridization, Fluorescence , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Mice , Mice, Inbred Strains , Models, Animal , Reoperation , Spleen/pathology , Transplantation ConditioningABSTRACT
The lymphatic vessels (lymphatics) play an important role in channeling fluid and leukocytes from the tissues to the secondary lymphoid organs. In addition to driving leukocyte egress from blood, chemokines have been suggested to contribute to leukocyte recirculation via the lymphatics. Previously, we have demonstrated that binding sites for several pro-inflammatory beta-chemokines are found on the endothelial cells (ECs) of lymphatics in human dermis. Here, using the MIP-1alpha isoform MIP-1alphaP, we have extended these studies to further support the contention that the in situ chemokine binding to afferent lymphatics exhibits specificity akin to that observed in vitro with the promiscuous beta-chemokine receptor D6. We have generated monoclonal antibodies to human D6 and showed D6 immunoreactivity on the ECs lining afferent lymphatics, confirmed as such by staining serial skin sections with antibodies against podoplanin, a known lymphatic EC marker. In parallel, in situ hybridization on skin with antisense D6 probes demonstrated the expression of D6 mRNA by lymphatic ECs. D6-immunoreactive lymphatics were also abundant in mucosa and submucosa of small and large intestine and appendix, but not observed in several other organs tested. In lymph nodes, D6 immunoreactivity was present on the afferent lymphatics and also in subcapsular and medullary sinuses. Tonsilar lymphatic sinuses were also D6-positive. Peripheral blood cells and the ECs of blood vessels and high endothelial venules were consistently nonreactive with anti-D6 antibodies. Additionally, we have demonstrated that D6 immunoreactivity is detectable in some malignant vascular tumors suggesting they may be derived from, or phenotypically similar to, lymphatic ECs. This is the first demonstration of chemokine receptor expression by lymphatic ECs, and suggests that D6 may influence the chemokine-driven recirculation of leukocytes through the lymphatics and modify the putative chemokine effects on the development and growth of vascular tumors.
Subject(s)
Endothelium, Lymphatic/metabolism , Neoplasms, Vascular Tissue/metabolism , Receptors, Chemokine/biosynthesis , Adult , Aged , Antibodies, Monoclonal/immunology , Chemokine CCL3 , Chemokine CCL4 , Dermis/immunology , Female , Humans , Intestines/immunology , Lymphoid Tissue/immunology , Macrophage Inflammatory Proteins/metabolism , Male , Membrane Glycoproteins/immunology , Membrane Glycoproteins/metabolism , Middle Aged , Neoplasms, Vascular Tissue/classification , Neoplasms, Vascular Tissue/pathology , Receptors, CCR10 , Receptors, Chemokine/genetics , Receptors, Chemokine/immunology , Skin/immunology , Skin/metabolism , Transcription, Genetic , Chemokine Receptor D6ABSTRACT
Members of the chemokine family of proteins mediate their biological effects through interaction with a family of seven-transmembrane G-protein-coupled receptors. This interaction is complicated by the biochemical properties of chemokines, such as their ability to form self aggregates and their ability to bind to proteoglycans. With some chemokines there is a clear interrelationship between these interactions; the chemokine platelet factor 4 binds preferentially to proteoglycans in its aggregated form. Little is known about the role of aggregation in the proteoglycan binding of other chemokines. Here we demonstrate that the aggregation status of the chemokine macrophage inflammatory protein 1alpha (MIP-1alpha) has no detectable effect on its affinity for proteoglycans. Furthermore, we demonstrate that the alteration of acidic amino acid residues in MIP-1alpha influences the affinity of its interactions with heparin as these residues are progressively neutralized, leading to an enhanced binding affinity for heparin. Thus, with MIP-1alpha, aggregation is not a determinant of proteoglycan binding; however, overall charge does seem to have a major role in the interaction. These results therefore add to our understanding of the nature of the interaction between MIP-1alpha and proteoglycans and suggests that the basic amino acids might not be the sole regulators of proteoglycan binding.
Subject(s)
Macrophage Inflammatory Proteins/metabolism , Proteoglycans/metabolism , Animals , Blotting, Western , Cells, Cultured , Chemokine CCL3 , Chemokine CCL4 , Chromatography, Affinity , Chromatography, Gel , Enzyme-Linked Immunosorbent Assay , Heparin/metabolism , Macrophage Inflammatory Proteins/chemistry , Mice , Protein ConformationABSTRACT
The difficulties associated with studying molecular mechanisms important in hemopoietic stem cell (HSC) function such as the problems of purifying homogeneous stem cell populations, have prompted us to adapt the murine ES cell system as an in vitro model of HSC generation and function. We now report that careful analysis of the time course of HSC generation in differentiating ES cells allows them to be used as a source of known and novel hemopoietic gene products. We have generated a subtracted library using cDNA from ES cells collected just prior to and just following the emergence of HSCs. Analysis of this library shows it to be a rich source of known hemopoietic and hemopoietic related gene products with 44% of identifiable cDNAs falling into these camps. We have demonstrated the value of this system as a source of novel genes of relevance to HSC function by characterizing a novel membrane protein encoding cDNA that is preferentially expressed in primitive hemopoietic cells. Intriguingly, further analysis of the known components of the subtracted library is suggestive of erythroid preconditioning of the ES cell-derived HSC. We have used dot-blot and in situ analysis to indicate that this erythroid preconditioning is probably restricted to primitive but not definitive HSC.
Subject(s)
Cell Differentiation , Embryo, Mammalian/cytology , Gene Expression Profiling , Stem Cells/cytology , Amino Acid Sequence , Animals , Base Sequence , Cell Line , DNA Primers , DNA, Complementary , Mice , Molecular Sequence Data , Sequence Homology, Amino Acid , Stem Cells/metabolism , Subtraction TechniqueABSTRACT
To enter its target cells, human immunodeficiency virus (HIV) must interact with CD4 and one of a family of chemokine receptors. CCR5 is widely used by the virus in this context, and its ligands can prevent HIV entry. Amino-terminal modified chemokine variants, in particular AOP-RANTES (aminooxypentane-linked regulated on activation normal T cell expressed and secreted), exhibit enhanced HIV entry inhibition. We have previously demonstrated that a non-allelic isoform of macrophage inflammatory protein (MIP)-1alpha, termed MIP-1alphaP, is the most active naturally occurring inhibitor of HIV entry known. Here we report the properties of a variant of MIP-1alphaP with an AOP group on the amino terminus. We show that, like RANTES, the addition of AOP to MIP-1alphaP enhances its interactions with CCR1 and CCR5, allows more effective internalization of CCR5, and increases the ligand's potency as an inhibitor of HIV entry through CCR5. Importantly, AOP-MIP-1alphaP is about 10-fold more active than AOP-RANTES at inhibiting HIV entry, making it the most effective chemokine-based inhibitor of HIV entry through CCR5 described to date. Surprisingly, the enhanced receptor interactions of AOP-MIP-1alphaP do not translate into increased chemotaxis or coupling to calcium ion fluxes, suggesting that this protein should be viewed as a partial, rather than a full, agonist for CCR1 and CCR5.
Subject(s)
Chemokines , HIV/metabolism , Macrophage Inflammatory Proteins/chemistry , Macrophage Inflammatory Proteins/pharmacology , Pentanes/chemistry , Animals , CHO Cells , Calcium/metabolism , Cell Line , Cell Membrane/metabolism , Chemokine CCL3 , Chemokine CCL4 , Chemokine CCL5/chemistry , Chemokine CCL5/pharmacology , Chemotaxis , Cricetinae , Dose-Response Relationship, Drug , Humans , Ligands , Protein Binding , Protein Isoforms , Receptors, CCR1 , Receptors, CCR5/metabolism , Receptors, Chemokine/metabolism , Signal Transduction , Time FactorsSubject(s)
Chemokines , Colony-Forming Units Assay/methods , Hematopoietic Stem Cells/cytology , Animals , Cell Division , MiceABSTRACT
A number of orphan G-protein coupled receptors (GPR) have been reported as putative chemokine receptors. One previously reported orphan receptor is an incomplete PCR clone, called GPR2. Here we report the cloning of full-length human (h)GPR2 and mouse (m)GPR2 cDNAs, and the identification of GPR2 as a receptor for a novel CC chemokine called ESkine. hGPR2 is expressed at high levels in testis and small intestine, and at lower levels in other tissues. mGPR2 was expressed at high levels in small intestine, colon, lymph nodes, and Peyer's patches and at lower levels in thymus and spleen. Stimulation of L1.2/hGPR2 transfectants with hESkine induced their migration and resulted in intracellular calcium mobilization. These results provide evidence that GPR2 is a specific receptor for ESkine. We propose that GPR2 be renamed as CCR10. The expression pattern of mGPR2/CCR10 suggests that it may play a role in the homing/trafficking of leukocytes within intestinal and lymphoid environments.
Subject(s)
Chemokines, CC/metabolism , Chemokines/metabolism , GTP-Binding Proteins/metabolism , Receptors, Chemokine/isolation & purification , Amino Acid Sequence , Animals , Calcium/metabolism , Cell Line , Cell Movement/immunology , Chemokine CCL27 , Chemokines/physiology , Cloning, Molecular , DNA, Complementary/isolation & purification , Humans , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Organ Specificity/genetics , Organ Specificity/immunology , Receptors, CCR10 , Receptors, Chemokine/biosynthesis , Receptors, Chemokine/genetics , TransfectionABSTRACT
Allergic reactions are characterized by the infiltration of tissues by activated eosinophils, Th2 lymphocytes, and basophils. The beta-chemokine receptor CCR3, which recognizes the ligands eotaxin, eotaxin-2, monocyte chemotactic protein (MCP) 3, MCP4, and RANTES, plays a central role in this process, and antagonists to this receptor could have potential therapeutic use in the treatment of allergy. We describe here a potent and specific CCR3 antagonist, called Met-chemokine beta 7 (Ckbeta7), that prevents signaling through this receptor and, at concentrations as low as 1 nM, can block eosinophil chemotaxis induced by the most potent CCR3 ligands. Met-Ckbeta7 is a more potent CCR3 antagonist than Met- and aminooxypentane (AOP)-RANTES and, unlike these proteins, exhibits no partial agonist activity and is highly specific for CCR3. Thus, this antagonist may be of use in ameliorating leukocyte infiltration associated with allergic inflammation. Met-Ckbeta7 is a modified form of the beta-chemokine macrophage inflammatory protein (MIP) 4 (alternatively called pulmonary and activation-regulated chemokine (PARC), alternative macrophage activation-associated C-C chemokine (AMAC) 1, or dendritic cell-derived C-C chemokine (DCCK) 1). Surprisingly, the unmodified MIP4 protein, which is known to act as a T cell chemoattractant, also exhibits this CCR3 antagonistic activity, although to a lesser extent than Met-Ckbeta7, but to a level that may be of physiological relevance. MIP4 may therefore use chemokine receptor agonism and antagonism to control leukocyte movement in vivo. The enhanced activity of Met-Ckbeta7 is due to the alteration of the extreme N-terminal residue from an alanine to a methionine.
Subject(s)
Adjuvants, Immunologic/physiology , Alanine/metabolism , Chemokines, CC/physiology , Methionine/metabolism , Peptide Fragments/immunology , Peptide Fragments/metabolism , Receptors, Chemokine/antagonists & inhibitors , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/metabolism , Adult , Alanine/genetics , Calcium/antagonists & inhibitors , Calcium/metabolism , Calcium Signaling/immunology , Cell Migration Inhibition , Chemokine CCL11 , Chemokines, CC/genetics , Chemokines, CC/metabolism , Chemotaxis, Leukocyte/immunology , Cloning, Molecular , Cytokines/metabolism , Eosinophils/metabolism , Humans , Iodine Radioisotopes/metabolism , Ligands , Methionine/genetics , Peptide Fragments/genetics , Receptors, CCR3 , Receptors, Chemokine/metabolism , Recombinant Proteins/biosynthesis , Tumor Cells, CulturedABSTRACT
Using the murine embryonal stem cell system, we have identified a novel gene encoding a highly divergent member of the beta-chemokine family of proinflammatory mediators and have called this protein ESkine. Much of the coding sequence for ESkine overlaps with the 3'-end of a novel interleukin 11 receptor alpha-like sequence on murine chromosome 4. ESkine is produced as two splice variants. One of these variants encodes a classical chemokine with an associated signal peptide, while the other variant (PESKY) possesses the main body of the chemokine but has replaced the signal peptide with an alternative stretch of amino acids that allows for nuclear targeting of this isoform. This differential splicing arises as a result of alternative 5' exon usage. These differentially spliced forms are expressed at discrete tissue loci. Thus, while ESkine is highly expressed in the placenta, PESKY is mainly expressed in the Testes and brain and weakly in the developing embryo. Studies on the proinflammatory properties of ESkine reveal it to be active in inducing polarization of CD4(+) T cells but to be inactive on other hemopoietic cellular populations.
Subject(s)
Alternative Splicing , Cell Nucleus/metabolism , Chemokines, CC/genetics , Chemokines/genetics , Protein Isoforms/genetics , Amino Acid Sequence , Base Sequence , CD4-Positive T-Lymphocytes/cytology , Cell Line , Cell Movement/physiology , Chemokine CCL27 , Chemokines/chemistry , Chemokines/physiology , Chemokines, CC/chemistry , Chemokines, CC/physiology , Humans , Molecular Sequence Data , Sequence Homology, Amino Acid , Subcellular Fractions/metabolismABSTRACT
All mature blood cells are derived from the haemopoietic stem cell (HSC). In common with all other haemopoietic cells, stem cells are mobile, and it is this property of mobility that has allowed bone marrow transplantation to become a routine clinical option. Successful transplantation requires haemopoietic stem cells to home to the bone marrow, leave the peripheral circulation and become stabilized in regulatory niches in the extravascular space of the bone marrow cavity. This homing and tethering process is reversible - haemopoietic stem cells can be released from their bone marrow tethering through changes in molecular interactions, which are also important in homing following transplantation. The molecular mechanisms regulating this two-way flow of stem cells are beginning to be elucidated, and much recent data has emerged that sheds light on the processes and molecules involved in these complex physiological events. This article reviews current knowledge of the adhesive, homing and proliferative influences acting on HSCs and progenitor cells.
Subject(s)
Cell Adhesion/physiology , Cell Movement/physiology , Hematopoietic Stem Cells/physiology , Animals , Antigens, CD/physiology , Bone Marrow/metabolism , Bone Marrow/physiology , Cell Adhesion Molecules/physiology , Cell Division/physiology , Hematopoietic Cell Growth Factors/physiology , Humans , Mice , Mice, Inbred NODABSTRACT
Chemokines play diverse roles in inflammatory and non-inflammatory situations via activation of heptahelical G-protein-coupled receptors. Also, many chemokine receptors can act as cofactors for cellular entry of human immunodeficiency virus (HIV) in vitro. CCR5, a receptor for chemokines MIP-1alpha (LD78alpha), MIP-1beta, RANTES, and MCP2, is of particular importance in vivo as polymorphisms in this gene affect HIV infection and rate of progression to AIDS. Moreover, the CCR5 ligands can prevent HIV entry through this receptor and likely contribute to the control of HIV infection. Here we show that a non-allelic isoform of human MIP-1alpha (LD78alpha), termed LD78beta or MIP-1alphaP, has enhanced receptor binding affinities to CCR5 (approximately 6-fold) and the promiscuous beta-chemokine receptor, D6 (approximately 15-20-fold). We demonstrate that a proline residue at position 2 of MIP-1alphaP is responsible for this enhanced activity. Moreover, MIP-1alphaP is by far the most potent natural CCR5 agonist described to date, and importantly, displays markedly higher HIV1 suppressive activity than all other human MIP-1alpha isoforms examined. In addition, while RANTES has been described as the most potent inhibitor of CCR5-mediated HIV entry, MIP-1alphaP was as potent as, if not more potent than, RANTES in HIV-1 suppressive assays. This property suggests that MIP-1alphaP may be of importance in controlling viral spread in HIV-infected individuals.
Subject(s)
Anti-HIV Agents/metabolism , HIV-1/drug effects , Macrophage Inflammatory Proteins/pharmacology , Receptors, Chemokine/metabolism , Amino Acid Sequence , Animals , Anti-HIV Agents/pharmacology , Cell Line , Chemokine CCL3 , Chemokine CCL4 , Chemokine CCL5/pharmacology , Humans , Macrophage Inflammatory Proteins/chemistry , Macrophage Inflammatory Proteins/genetics , Mice , Molecular Sequence Data , Protein Binding , Receptors, CCR1 , Receptors, CCR10 , Receptors, CCR5/metabolism , Chemokine Receptor D6ABSTRACT
We have assessed expression of MIP-1alpha binding sites on the surface of CD34+ cells from normal bone marrow (NBM) and chronic myeloid leukemia (CML) peripheral blood. This study has highlighted a small subpopulation of CD34+ (15.7 +/- 6.2% in NBM and 9 +/- 4% in CML), which has specific macrophage-inflammatory protein-1alpha (MIP-1alpha) cell surface binding sites. Further phenotypic characterization of the receptor-bearing cells has shown that they do not express the Thy-1 Ag, suggesting that they are committed progenitor cells rather than CD34+ Thy+ stem cells. However, more than 80% of methanol-fixed CD34+ cells do bind MIP-1alpha, suggesting that these cells may possess a pool of internal receptors, although we were unable to induce cell surface expression by cytokine stimulation. The percentage of these CD34+, MIP-1alpha-R+ cells present in the CD34 compartment of NBM is significantly higher than in CML, implicating lack of binding sites as part of the mechanism for the loss of response to this chemokine seen in CML. Specific Ab to the MIP-1alpha receptor implicated in HIV infection, CCR5, revealed that very few CD34+ cells expressed these receptors and that expression was confined to the CD34+ Thy- progenitor population. Data presented in this work suggest that active binding sites for the stem cell growth inhibitor MIP-1alpha are not constitutively expressed on the surface of most resting primitive multipotent cells, and that these cells are not potential targets for HIV-1 infection through CCR5.
Subject(s)
Antigens, CD34/isolation & purification , Hematopoietic Stem Cells/chemistry , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Macrophage Inflammatory Proteins/metabolism , Receptors, Chemokine/isolation & purification , Blood Cells/chemistry , Cell Compartmentation , Chemokine CCL3 , Chemokine CCL4 , Humans , Microscopy, Immunoelectron , Receptors, CCR3 , Receptors, CCR5/metabolismABSTRACT
The beta-chemokine macrophage inflammatory protein-1 alpha (MIP-1alpha) and its associated receptors are involved in the regulation of pro-inflammatory and haemopoietic processes. This study was designed to investigate regulation of expression MIP-1alpha and its receptors by other haemopoietic cytokines. Murine bone marrow macrophages (BMM) were treated with or without GM-CSF or IL-3 and expression of MIP-1alpha, other chemokines and their receptors examined by Northern blotting. Receptor levels were also examined using Scatchard analysis and functional tests. Treatment of BMM with GM-CSF revealed a striking increase in MIP-1alpha mRNA levels, relative to untreated cells with a corresponding increase in MIP-1alpha protein. A similar increase in mRNA levels was found when BMM were treated with IL-3. An increase in the expression of three other beta-chemokines namely MIP-1beta, MCP-1 and MCP-3, was also found following treatment with GM-CSF or IL-3. We have additionally examined the expression of the known beta-chemokine receptors in BMM and observed an increase in CCR1 mRNA levels following treatment with GM-CSF and IL-3, but no change was seen in the level of CCR5 expression. The increase in CCR1 expression was reflected in an increase in the number of cell surface receptors for MIP-1alpha on the GM-CSF treated BMM and in an enhanced response of the GM-CSF treated BMM to CCR1 ligands. These data suggest that GM-CSF and IL-3 may be involved in mechanisms regulating expression levels of MIP-1alpha and its receptors.
Subject(s)
Bone Marrow Cells/metabolism , Chemokines/biosynthesis , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Interleukin-3/pharmacology , Macrophage Inflammatory Proteins/metabolism , Macrophages/metabolism , Receptors, Chemokine/biosynthesis , Animals , Cells, Cultured , Chemokine CCL3 , Chemokine CCL4 , Female , MiceABSTRACT
The maintenance of the various blood cell populations in mammals is achieved by the proliferation and differentiation of precursor cells located primarily in the bone marrow. These precursor cells are all derived from a common haemopoietic stem cell population that is established during embryogenesis and functions for the lifetime of the organism. An overview is given of the various assay systems for haemopoietic stem cells, how these assays have contributed to understanding the considerable heterogeneity within the stem cell compartment, the regulation of stem cells and the development of the haemopoietic system.